We have relied on certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable based on our management’s knowledge of the industry. Forecasts are particularly likely to be inaccurate, especially over long periods of time.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Stage not disclosed · ActiveModality: orally bioavailable small molecule
Aliases CF101
Target A3AR (adenosine A3 receptor)
Indications
Plaque Psoriasis(Phase 3)
Lowe Syndrome(Phase 3)
Status note Most advanced molecule per filing, but no current trial or indication stated in excerpts. Failure history (per risk factors): Phase 3 dry-eye missed primary (complete corneal clearing); Phase 2 glaucoma no IOP separation; two Phase 2b RA studies missed primaries; Phase 3 ACROBAT (RA) ended on IDMC interim recommendation; Phase 2/3 psoriasis missed primary (further analysis suggests potential in moderate-severe psoriasis). No explicit discontinuation.
Namodenoson
Stage not disclosed · ActiveModality: orally bioavailable small molecule
Aliases CF102
Target A3AR (adenosine A3 receptor)
Indications
Hepatocellular Carcinoma(Phase 3)
Cirrhosis(Phase 3)
Pancreatic Adenocarcinoma(Phase 3)
Status note Among the two most advanced molecules; no current trial or indication stated in excerpts. Failure history (per risk factors): Phase 2 in advanced HCC (Child-Pugh B, post-Nexavar) missed its primary endpoint. No explicit discontinuation.
CF602
Stage not disclosed · ActiveModality: orally bioavailable small molecule
Target A3AR (adenosine A3 receptor)
Status note Third pipeline molecule in the A3AR platform; no stage, trial, or indication stated in excerpts.
Per-asset detail extracted from the 20-F filed 2026-03-26. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.